Study of lead program will provide proof-of-concept to enable further clinical development in severe autoimmune diseases; full cohort data available in 2H'23 DNTH103 is a next-generation monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback